Advertisement

European Journal of Clinical Pharmacology

, Volume 8, Issue 6, pp 393–401 | Cite as

Treatment of benign essential hypertension

Comparison of furosemide and hydrochlorothiazide
  • K. Valmin
  • T. Hansen
Originals

Summary

Furosemide (Impugan®) 12.5, 25 or 40 mg twice daily, has been compared as an antihypertensive with hydrochlorothiazide 12.5 mg twice daily and a placebo. A double blind, cross-over design was used with a run-in period of 4 weeks, preceding five 4-week periods of treatment with these compounds alone. There were 34 patients in the trial, 17 men and 17 women. Paired comparison showed that furosemide 25 or 40 mg twice daily and hydrochlorothiazide 12.5 mg twice daily had a similar hypotensive effect, irrespective of the initial blood pressure. Furosemide 40 mg twice daily and hydrochlorothiazide 12.5 mg twice daily caused a slight fall of blood pressure as compared with placebo (0.10>p>0.05, p<0.05). There was a distinct correlation between blood pressure and age. Serum K+ fell significantly during treatment, particularly with hydrochlorothiazide 12.5 mg twice daily, as well as with furosemide 25 or 40 mg twice daily. As compared with placebo, urinary output increased significantly after furosemide 12.5, 25 or 40 mg twice daily, but it rose only to a non-significant extent after hydrochlorothiazide. The fall of blood pressure and decrease in serum K+ were linearly related. There were only a few, mild side effects which did not necessitate discontinuation of the trial.

Key words

Furosemide hydrochlorothiazide essential hypertension blood pressure serum electrolytes urinary output 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pardo, E.G., Vargas, R., Vidrio, H.: Antihypertensive drug action. Ann. Rev. Pharmacol.5 77–92 (1965)Google Scholar
  2. 2.
    Peters, G.: Pharmacology of diuretics. In: Antihypertensive therapy (eds. Gross, F., Naegeli, S.R., Kirkwood, A.H.), pp. 31–58. Berlin, Heidelberg, New York: Springer-Verlag 1966Google Scholar
  3. 3.
    Villarreal, H., Exaire, J.E., Revollo, A., Soni. J.: Effects of chlorothiazide on systemic hemodynamics in essential hypertension. Circulation26 405–408 (1962)Google Scholar
  4. 4.
    Beevers, D.G., Hamilton, M., Harpur, J.E.: The long-term treatment of hypertension with thiazide diuretics. Postgrad. med. J.47 639–643 (1971)Google Scholar
  5. 5.
    Kjaerulff, J., Lyngsφe, J.: Den antihypertensive virkning af bendroflumetiazid, hydroflumetiazid, triklormetiazid, klortalidon og furosemid. Ugeskr. Laeg.135 1744–1746 (1973)Google Scholar
  6. 6.
    Garde, K., Lindahl, A.: Etakrynsyre og fursemid anvendt i behandling af hypertension. En sammenligning med klortalidon. Ugeskr. Laeg.35 1071–1075 (1965)Google Scholar
  7. 7.
    Anderson, J., Godfrey, B.E., Hill, D.M., Munro-Faure, A.D., Sheldon, J.: A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. Quart. J. Med.40 541–560 (1971)Google Scholar
  8. 8.
    Wertheimer, L., Finnerty, F.A., Bercu, B.A., Hall, R.H.: Furosemide in essential hypertension. Arch. intern. Med.127 934–938 (1971)Google Scholar
  9. 9.
    Johnston, L.C., Santos, D.E., Gantt, C.: The antihypertensive properties of furosemide on chronic oral administration. J. clin. Pharmacol.10 121–125 (1970)Google Scholar
  10. 10.
    Atkins, L.L.: Furosemide in the treatment of geriatric patients. Geriatrics21 143–149 (1966)Google Scholar
  11. 11.
    Hammarström, S.: Kliniska erfarenheter av fursemid. Läkartidningen62 62–68 (1965)Google Scholar
  12. 12.
    Hutcheon, D.E., Leonard, G.: Diuretic and antihypertensive actions of furosemide. J. clin. Pharmacol.7 26–33 (1967)Google Scholar
  13. 13.
    Bratton, A.C., Marshall, E.K.: A new coupling component for sulfanilamide determination. J. biol. Chem.128 537–550 (1939)Google Scholar
  14. 14.
    Wilson, I.M., Freis, E.D.: Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation20 1028–1036 (1959)Google Scholar
  15. 15.
    Conway, J., Lauwers, P.: Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation21 21–27 (1960)Google Scholar
  16. 16.
    Lauwers, P., Conway, J.: Effects of long-term treatment with chlorothiazide on body fluids, serum electrolytes and exchangeable sodium in hypertensive patients. J. Lab. clin. Med.56 401–408 (1960)Google Scholar
  17. 17.
    Gifford, R.W., Mattox, V.R., Orvis, A.L., Sones, D.A., Resevear, J.W.: Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation24 1197–1205 (1961)Google Scholar
  18. 18.
    Hansen, J.: Hydrochlorothiazide in the treatment of hypertension. The effects on blood volume, exchangeable sodium and blood pressure. Acta med. scand.183 317–321 (1968)Google Scholar
  19. 19.
    Leth, A.: Aendringer i plasma og ekstracellulaervolumen hos patienter med essentiel hypertension i langtidsterapi med hydroklortiazid. Nord. Med.84 1042–1046 (1970)Google Scholar
  20. 20.
    Leth, A.: Changes in plasma and extracellular fluid volumes in patients with essential hypertension during long-term treatment with hydrochlorothiazide. Circulation42 479–485 (1970)Google Scholar
  21. 21.
    Tarazi, R.C., Dustan, H.P., Frohlich, E.D.: Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation41 709–717 (1970)Google Scholar
  22. 22.
    Lund-Johansen, P.: Hemodynamic changes in long-term diuretic therapy of essential hypertension. A comparative study of chlorthalidone, polythiazide and hydrochlorothiazide. Acta med. scand.187 509–518 (1970)Google Scholar
  23. 23.
    Healy, J.J., McKenna, T.J., Canning, B.St.J., Brien, T.G., Duffy, G.J., Muldowney, F.P.: Body composition changes in hypertensive subjects on long-term oral diuretic therapy. Brit. med. J.1970 I 716–719Google Scholar
  24. 24.
    Finnerty, F.A.: Relationship of extracellular fluid volume to the development of drug resistance in the hypertensive patient. Amer. Heart J.81 563–565 (1971)Google Scholar
  25. 25.
    Degnbol, B., Dorph, S., Marner, T.: Virkningen af forskellige diuretika pa forhφjet blodtryk og serum-kalium. Ugeskr. Laeg.133 287–290 (1971)Google Scholar
  26. 26.
    Bartorelli, C., Cargano, N., Leonetti, G.: Potassium loss and potassium replacement during long-term diuretic treatment in hypertension. In: Antihypertensive therapy (eds. Gross, F., Naegeli, S.R., Kirkwood, A. H.) pp. 422–435. Berlin, Heidelberg, New York: Springer-Verlag 1966Google Scholar
  27. 27.
    Grieble, H.G., Johnston, L.C.: Treatment of arterial hypertensive disease with diuretics. I. Effects on blood pressure of bendroflumethiazide, potassium chloride, and spironolactone. Arch. intern. Med.110 64–71 (1962)Google Scholar
  28. 28.
    Grieble, H.G., Johnston, L.C., Fuller, J.B.: Treatment of arterial hypertensive disease with diuretics. II. Effects on electrolytes and uric acid of bendroflumethiazide, potassium chloride, and spironolactone. Arch. intern. Med.110 72–82 (1962)Google Scholar
  29. 29.
    Fritel, D., Quichaud, J., Hodara, M., Truffert, J.: Etude du mécanisme d'action de l'hydrochlorothiazide dans l'hypertension artérielle; role de l'hypokaliémie. Rev. Franc. études Clin. biol.6 560–573 (1961)Google Scholar
  30. 30.
    Olesen, K.H.: Blodtryksfald og kaliumbalance under tiazidbehandling af arteriel hypertension. Ugeskr. Laeg.133 305–306 (1971)Google Scholar
  31. 31.
    Kochar, M.S., Itskovitz, H.D.: Effects of hydrochlorothiazide in hypertensive patients and the need for potassium supplementation. Curr. ther. Res.15 298–304 (1973)Google Scholar

Copyright information

© Springer-Verlag 1975

Authors and Affiliations

  • K. Valmin
    • 1
    • 2
    • 3
  • T. Hansen
    • 1
    • 2
  1. 1.Medical ClinicCentral HospitalVäxjöSweden
  2. 2.Department of Biology, DumexCopenhagenDenmark
  3. 3.St. Sigfrids sjukhus FackVäxjöSweden

Personalised recommendations